source
- GSK to acquire Chimagen’s trispecific T-cell engager program in deal up to $750 millionGSK announced it will acquire a preclinical trispecific T cell engager program from Chinese biotech Chimagen Biosciences in a transaction that could total up to $750 million. The agreement provide…
- Medicare AI prior-authorization pilot plagued by rollout glitches, causing care delaysDocuments obtained through a Freedom of Information Act lawsuit reveal that the Medicare program using artificial intelligence for prior authorization was launched hastily and suffered numerous tec…